Top London Dental Institute to use Michelson’s VivoSight Probe to Assess Dental Implant Viability
(Orpington, UK) June 9, 2010 -- Michelson Diagnostics Ltd has delivered a VivoSight Multi-Beam OCT scanner to Kings College London Dental Institute for a project that promises to solve one of the biggest problems of modern dentistry; how to determine when a dental implant is at risk of failure. By using VivoSight to provide real time, high resolution in vivo images of hard and soft tissue, researchers hope to quickly identify prompt, non-invasive treatment protocols versus expensive, stressful and invasive procedures.
“When a dental implant starts to fail, the soft tissue around it becomes infected and changes character,” explained Professor Tim Watson, who is leading the project. “Dentists need a method of imaging these changes and detecting them before they have become irreversible, but X-ray and cone-beam CT images do not show sufficient detail. Our project aims to solve this by combining the ability of Multi-Beam Optical Coherence Tomography (OCT) to image soft tissue microstructure, with the ability of vascular micro-endoscopy to image blood vessels.”
The failure of dental implants is a rapidly growing and very expensive oral healthcare problem. Tens of thousands of implants are placed annually, but many fail after only a few years, when an infection develops at the surface and then penetrates between the gum and titanium implant materials. If not picked up in time and promptly treated, the infection can damage the implant-bone interface, resulting in loosening and ultimately loss of the implant, with accompanying pain and distress to the patient. Repair and replacement costs can run to £thousands.
The one-year project aims to prove that non-invasive image data can be captured in-vivo, detecting infected tissues, so that a practical instrument can be developed and marketed. The £100k project is funded from the £10.5M awarded to King’s College London as one of four Centres of Excellence in Medical Engineering by Wellcome Trust and EPSRC. The funding will help to develop integrated teams of clinicians, biomedical scientists and world-class engineers with the capacity to invent high-tech solutions to medical challenges, potentially improving thousands of patients’ lives. Professor Reza Razavi, Head of Imaging Sciences at King’s and the new Centre said: ‘Our Medical Engineering Centre will break down the barriers between engineering, the physical sciences, and biology and medicine. We will conduct world-class clinical trials to show the benefit of new discoveries in imaging technology that the centre will produce. I see patients in my clinic every day, so I have a very clear understanding of what they need to make their lives better. Medical imaging has the capacity to give my patients access to new tools for earlier and more precise diagnoses of cancer and heart disease, better targeted therapies, less invasive surgery, and improved techniques for rebuilding tissue after surgery.”
About King’s College London Dental Institute
King’s College London Dental Institute is the largest dental academic centre in the UK. They train a quarter of all new dentists in the UK and with their innovative approach to online learning provide professional training to dentists from 40 countries world-wide. Their excellence in teaching and research is reflected by top ratings in the latest QAA and RAE reviews. Their dynamic multidisciplinary approach to both teaching and research is demonstrated in pioneering work ranging from craniofacial biology through to clinical service provision and innovations in dental education.
Website : http://www.kcl.ac.uk/schools/dentistry/
Contact: Dr Richard J Cook,
About Michelson Diagnostics
Michelson Diagnostics was founded in 2006; it is privately owned and based in Kent, U.K. The company develops imaging products using a technology called Multi-Beam Optical Coherence Tomography. The company’s products include the EX1301 OCT Microscope which is used by researchers in a variety of fields including genetics research, tissue engineering and industrial metrology; and the VivoSight OCT scanner which has CE and 510(k) clearance for use to aid clinical judgments in the field of dermatology. Applications of VivoSight include guiding skin cancer surgery and blood vessel imaging for assessing laser treatment effectiveness.
Further information about Michelson Diagnostics is available on the Internet at http://www.md-ltd.co.uk/ or by email to email@example.com.
For clinical use in the US FDA 510(k) K093520 applies:
The VivoSight Topical OCT system is indicated for use in the two-dimensional, cross-sectional, real-time imaging of external tissues of the human body. This indicated use allows imaging of tissue microstructure, including skin, to aid trained and competent clinicians in their assessment of a patient's clinical conditions. US Federal law restricts this device to sale by or on the order of a physician.
The Michelson Diagnostics logo and the VivoSight name are the trademarks of Michelson Diagnostics Ltd and are registered in the UK, the US & throughout the European Union.